Table 3. Patients with idiopathic TGCV with pseudonormalization of BMIPP-WR.
| Age | Sex | Condition at pseudonormalization |
BMIPP-WR (%) | |||
|---|---|---|---|---|---|---|
| At diagnosis | Pseudonormalization | After treatment | ||||
| Case 1 | 81 | F | CABG failure | 4.1 | 25.2 | 8.9 |
| Case 2 | 75 | M | Frequentspast ic angina | −5.5 | 12.6 | 7.0 |
| Case 3 | 72 | F | Subtotal occlusion of LAD | ND | 24.3 | 5.0 |
| Case 4 | 43 | F | AMI (RCA #4) | 2.8 | 9.4 | 4.1 |
| Case 5 | 40 | M | CABG failure | 3.1 | 21.5 | ND |
Cases 1 and 2 are No. 024 and No. 023 paticipants, respectively, in the placebo group of the phase lla trial (please see Figure 1B).
Case 3 was reported previously by the Japan TGCV study group in the reference 16.
The principal investigator has obtained the information of cases 4–5 from the Japan TGCV study group after the phase lla trial was finished.
The pseudonormalization disappeared in Cases 1–4 after the revasculization or optimized medical therapy.
AMI: acute myocardial infarction, BMIPP: beta-methyliodophenylpentadecanoic acid, CABG: coronary artery bypass graft, LAD: left anterior descending branch, ND: not done, RCA: right coronary artery, TGCV: triglyceride deposit cardiomyovasculopathy, WR: washout rate